Showing results (51-60 of 79) with videos related to

Sort By:
Pageof 8
Endocrine-Related Cancer|September 16, 2015
Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancerFrancis Worden, Martin Fassnacht, Yuankai Shi, et al.
Frontiers in Oncology|March 20, 2026
Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer after prior vascular endothelial growth factor receptor-targeted therapy (COSMIC-311): outcomes by BRAF statusMarcia S Brose, Bhumsuk Keam, Jolanta Krajewska, et al.
The Lancet. Oncology|March 30, 2019
Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trialVicky Makker, Drew Rasco, Nicholas J Vogelzang, et al.
Journal for Immunotherapy of Cancer|January 19, 2024
Evaluation of potential biomarkers for lenvatinib plus pembrolizumab among patients with advanced endometrial cancer: results from Study 111/KEYNOTE-146Vicky Makker, Matthew H Taylor, Carol Aghajanian, et al.
BMC Cancer|June 7, 2022
Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinibJames C H Yang, Marcia S Brose, Gilberto Castro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2024
Durability of Response With Selpercatinib in Patients With <i>RET</i>-Activated Thyroid Cancer: Long-Term Safety and Efficacy From LIBRETTO-001Lori J Wirth, Marcia S Brose, Vivek Subbiah, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2007
A 10-gene classifier for distinguishing head and neck squamous cell carcinoma and lung squamous cell carcinomaAnil Vachani, Michael Nebozhyn, Sunil Singhal, et al.
Lancet (London, England)|April 29, 2014
Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trialMarcia S Brose, Christopher M Nutting, Barbara Jarzab, et al.
The Oncologist|May 10, 2022
Larotrectinib Treatment for Patients With TRK Fusion-Positive Salivary Gland CancersXiuning Le, Christina Baik, Jessica Bauman, et al.
Cancer Medicine|December 5, 2022
Health-related quality-of-life analyses from a multicenter, randomized, double-blind phase 2 study of patients with differentiated thyroid cancer treated with lenvatinib 18 or 24 mg/dayMatthew H Taylor, Sophie Leboulleux, Yury Panaseykin, et al.
Pageof 8